Crinetics Pharmaceuticals (CRNX)

Its lead commercial product is Palsonify, the brand name for paltusotine, a once-daily oral therapy for adults with acromegaly who have not achieved adequate control after surgery or for whom surgery is not an option. Acromegaly is a rare disorder typically caused by excess growth hormone, often from a pituitary tumour, and treatment can require lifelong management. An oral option is significant because many existing therapies involve injections or procedures, creating an opportunity for convenience and adherence benefits if clinical outcomes are maintained.

Crinetics also has a pipeline aimed at additional endocrine disorders. Atumelnant is a late-stage investigational candidate being studied for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, both of which involve abnormal hormone production and can cause serious metabolic and cardiovascular complications. Another programme, CRN09682, is being developed for somatostatin receptor subtype 2-expressing neuroendocrine tumours and other solid tumours with similar biology.

The company’s broader strategy is to use its discovery platform to create targeted oral therapies for rare endocrine indications where specialist physicians can identify patients clearly. As a commercial-stage pharmaceutical business, Crinetics combines marketed-product execution with the clinical and regulatory risks typical of drug development.